Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR HFA versus CUTIVATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR HFA versus CUTIVATE.
ADVAIR HFA vs CUTIVATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
Glucocorticoid receptor agonist; modulates gene expression to inhibit inflammatory mediators, vasoconstriction, and immunosuppression.
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
Apply a thin layer to affected skin areas once or twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
None Documented
None Documented
Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours.
2-4 hours (terminal elimination half-life); short half-life supports twice-daily dosing for maintenance of clinical effect.
Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%.
Primarily hepatic metabolism; metabolites are excreted renally and fecally. Unchanged drug is negligible in urine. Route: renal (~60% as metabolites), fecal (~40% as metabolites).
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid